Sarepta Therapeutics (SRPT) Long-Term Debt Issuances (2014 - 2025)

Sarepta Therapeutics (SRPT) posted Long-Term Debt Issuances of $35.1 million for Q4 2025, up 102.53% on a QoQ basis from $17.3 million in Q4 2018.

Analysis

Sarepta Therapeutics (SRPT) Long-Term Debt Issuances (2014 - 2025) Analysis & Trends

Sarepta Therapeutics has reported Long-Term Debt Issuances for 6 years, with the latest figure at $35.1 million in Q4 2025.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $35.1 million in Q4 2025; TTM through Dec 2025 was $35.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $158.4 million, changed N/A from the prior year.
Long-Term Debt Issuances was $35.1 million for Q4 2025 at Sarepta Therapeutics, up from $17.3 million in the prior quarter.
The five-year high for Long-Term Debt Issuances was $35.1 million in Q4 2025, with the low at $35.1 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Krystal Biotech	10.60 Bn	9.76 Bn	112.79 Mn	-
2	CRISPR Therapeutics AG	5.39 Bn	5.39 Bn	-	-
3	Iovance Biotherapeutics	3.98 Bn	3.68 Bn	55.72 Mn	-
4	Legend Biotech	3.97 Bn	3.00 Bn	251.50 Mn	-
5	uniQure	3.09 Bn	3.09 Bn	5.49 Mn	-
6	Beam Therapeutics	3.06 Bn	3.06 Bn	-	-
7	Precigen	2.54 Bn	2.54 Bn	52.17 Mn	-
8	Sarepta Therapeutics	2.38 Bn	1.58 Bn	251.87 Mn	-
9	Vericel	2.06 Bn	1.89 Bn	56.40 Mn	-
10	Taysha Gene Therapies	1.82 Bn	1.82 Bn	-	-

Historic Data

Download Data